Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis
about
Interferon beta versus glatiramer acetate for relapsing-remitting multiple sclerosisNew and emerging immune-targeted drugs for the treatment of multiple sclerosisSubcutaneous recombinant interferon-β-1a (Rebif®): a review of its use in the treatment of relapsing multiple sclerosis.Two decades of subcutaneous glatiramer acetate injection: current role of the standard dose, and new high-dose low-frequency glatiramer acetate in relapsing-remitting multiple sclerosis treatment.Targeting NOX enzymes in the central nervous system: therapeutic opportunities.Multiple sclerosis and pregnancy: maternal considerations.When to initiate disease-modifying drugs for relapsing remitting multiple sclerosis in adults?Tolerogen-induced interferon-producing killer dendritic cells (IKDCs) protect against EAE.Differential glatiramer acetate treatment persistence in treatment-naive patients compared to patients previously treated with interferon.Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.Interferon beta and glatiramer acetate therapy.Interferon-beta-1b-induced short- and long-term signatures of treatment activity in multiple sclerosis.Fingolimod for the treatment of relapsing multiple sclerosis.Biologic therapies in non-rheumatic diseases: lessons for rheumatologists?Dimethyl fumarate : a Janus-faced substance?The pharmacokinetics of glatiramer acetate for multiple sclerosis treatment.Glatiramer acetate: a review of its use in patients with relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis.B cells and their cytokine activities implications in human diseases.The Use of Oral Disease-Modifying Therapies in Multiple Sclerosis.Clinical utility of glatiramer acetate in the management of relapse frequency in multiple sclerosis.Glatiramer acetate guards against rapid memory decline during relapsing-remitting experimental autoimmune encephalomyelitis.Acute liver injury in a Glatopa-treated patient with MS.Altered expression of the plasminogen activation pathway in peripheral blood mononuclear cells in multiple sclerosis: possible pathomechanism of matrix metalloproteinase activation.Oligodendrogenesis and myelinogenesis during postnatal development effect of glatiramer acetate.Drugs approved for the treatment of multiple sclerosis: review of their safety profile.Contribution of endermology to improving indurations and panniculitis/lipoatrophy at glatiramer acetate injection site.Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis: the impact of genome-wide association studies identified disease risk loci
P2860
Q24194800-3A799AD6-3696-4BDC-87C8-132AFC1829F5Q26997067-3977B15F-16BD-4CDA-97CD-EFC24C8D5167Q34028864-16CDFC48-B58B-488D-B50B-D28AC6260F08Q34090086-2E1BEB97-8671-4AF7-A5B5-B16AB640116CQ34285497-1720DF60-8ABA-4371-8C2D-F825F75B2F75Q34639869-462E42F6-70BF-4D5B-AB1F-20D8CAB3FE86Q35374052-16FF5FBD-315C-4606-831D-3ED08512E35FQ35610755-F8462880-03AC-4873-91A0-9C9954690241Q35749670-B829B2DA-0040-4062-A5C5-5255F4D79051Q36202727-83E13BB8-2D11-46B4-80A2-3C7B6AC20F03Q36568660-AAB5BDE9-D8E0-4754-8B7A-5E64DB6560C2Q37221728-96BC5280-8DC1-48E0-9EC4-57E812B20E2FQ37821010-4F4F9F32-5202-4AEB-84C3-1966BEC2AB58Q37909907-2E72B3F6-8D48-4183-88D3-0CB31FCF01E2Q38108633-2DB0A166-1FDD-4D73-87EC-E590445B413BQ38116543-DFAD3718-4151-4B45-AD12-EC35F1360526Q38152977-8AA23CB0-3A72-4ABF-BA7F-310BF05B4F6FQ38665740-2AEE2D0D-69F8-4C0F-AB2A-550EAE3CB93DQ38761495-81B79331-274A-4E1B-B613-5F55D9760C4FQ39672574-4DD5650F-ADF4-4958-9F63-993EBFE3D1E8Q41721584-041636C2-5D99-4B79-9F8A-624CB921121FQ42220529-520B9437-BFCA-460B-A798-6020D09D48FCQ46149675-A2143031-22C3-48B1-BCF1-784E1D7700D8Q47804554-CC09A573-125B-4D57-8AAE-DBA90DC35524Q47868767-7B320126-B51B-430F-9EFF-012F0D48FE06Q51355985-E8A6CA2C-AED8-49FD-8ADE-758195BA4A80Q57417451-1943287E-2725-4367-8E7D-4A76129ACD86
P2860
Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Glatiramer acetate: a review o ...... ly definite multiple sclerosis
@ast
Glatiramer acetate: a review o ...... ly definite multiple sclerosis
@en
Glatiramer acetate: a review o ...... ly definite multiple sclerosis
@nl
type
label
Glatiramer acetate: a review o ...... ly definite multiple sclerosis
@ast
Glatiramer acetate: a review o ...... ly definite multiple sclerosis
@en
Glatiramer acetate: a review o ...... ly definite multiple sclerosis
@nl
prefLabel
Glatiramer acetate: a review o ...... ly definite multiple sclerosis
@ast
Glatiramer acetate: a review o ...... ly definite multiple sclerosis
@en
Glatiramer acetate: a review o ...... ly definite multiple sclerosis
@nl
P2860
P1433
P1476
Glatiramer acetate: a review o ...... ly definite multiple sclerosis
@en
P2093
Natalie J Carter
P2860
P304
P356
10.2165/11204560-000000000-00000
P407
P577
2010-08-20T00:00:00Z
P6179
1008434565